Modulate c-myc/CD47 axis; Downregulate CD47 expression at transcriptional level by suppressing c-myc expression; Enhance the phagocytosis of macrophages to eliminate tumor cells; Enhance the efficiency of anti-CD47 antibody and rituximab-mediated phagocytosis. This evidence concerns the gene CD47 and neoplasm.